⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 22, 2025Open Access

Table S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

John D. Powderly Martina Imbimbo Antoîne Italiano Patricia Martín-Romano Meredith McKean Teresa Macarulla Eduardo Castañón Álvarez Benedito A. Carneiro Raymond Mager Vicky Barnhart Steven Eck Elina Murtomaki Arsène‐Bienvenu Loembé Yun He Zachary A. Cooper Eric Tu Chunling Fan Agnes Boyer Chamard Carine Paturel Paula G. Fraenkel Antoine Hollebecque

View Full Paper

Ask AI

Bookmark

Share

Key Points

TEAEs occurred in over 10% of all patients, highlighting safety concerns associated with treatments.
Combination therapy with anti-CD39 mAb and durvalumab was assessed in patients with advanced solid tumors.
This observational analysis provides insights into adverse events from these cancer therapies.
Findings may guide future treatment strategies for managing advanced solid tumors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Monotherapy and combination therapy impact adverse events in patients with advanced solid tumors.

Abstract

TEAEs of any grade occurring in >10% of all patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Powderly et al. (2025) studied this question.

synapsesocial.com/papers/68d4725631b076d99fa6b12d https://doi.org/10.1158/2767-9764.30177703

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
2Table S3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
3Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
4Table S5 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
5Table S4 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025

Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
Supplementary Appendix from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025